Letter: infliximab concentrations during induction therapy-one size does not fit all
- PMID: 29644743
- PMCID: PMC6375710
- DOI: 10.1111/apt.14616
Letter: infliximab concentrations during induction therapy-one size does not fit all
Conflict of interest statement
Comment on
-
Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy.Aliment Pharmacol Ther. 2018 Jan;47(2):212-218. doi: 10.1111/apt.14410. Epub 2017 Nov 9. Aliment Pharmacol Ther. 2018. PMID: 29124774
References
-
- Papamichael K, Casteele NV, Ferrante M, et al. Therapeutic drug monitoring during induction of anti-tumor necrosis factor therapy in inflammatory bowel disease: defining a therapeutic drug window. Inflamm Bowel Dis 2017;23:1510–5. - PubMed
-
- Brandse JF, Mathot RA, van der Kleij D, et al. Pharmacokinetic features and presence of anti-drug antibodies associate with response to infliximab induction therapy in patients with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2016;14:251–8. - PubMed
-
- Davidov Y, Ungar B, Bar-Yoseph H, et al. Association of induction infliximab levels with clinical response in perianal Crohn’s disease. J Crohns Colitis 2017;11:549–555 - PubMed
-
- Bar-Yoseph H, Levhar N, Selinger L, et al. Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy. Aliment Pharmacol Ther 2018; 47:212–218 - PubMed
-
- Adedokun OJ, Sandborn WJ, Feagan BG, et al. Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitis. Gastroenterology 2014;147:1296–307.e5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical